KLOW (Blend)
Equal Milligrams Is Not Equal Molecules
A blend's total mass says nothing about how many molecules of each component it contains, because the components differ in molecular weight. In KLOW the range is 342 to 1,420 daltons, so an equal-mass split and an equimolar split are four-fold apart.
Key facts
- KPV
- 342.43 Da, CID 125672
- GHK-Cu
- 402.92 Da, CID 71587328
- TB-500
- 889.0 Da, CID 62707662
- BPC-157
- 1419.5 Da, CID 9941957
- Ratio of largest to smallest
- 4.15
- Micromoles per mg, KPV
- 2.92
- Micromoles per mg, BPC-157
- 0.704
- Stated split in the product
- None
Why a total mass is an ambiguous instruction
KLOW is described by a single number: 80mg, across four components. That number is a mass, and mass is not what a receptor, a transporter or an enzyme responds to - molecules are. Because the four components differ substantially in molecular weight, converting the one into the other changes the answer by a large factor, and the direction of the change depends entirely on an assumption the label does not settle. Two people can read the same 80mg honestly and reasonably and arrive at compositions that differ four-fold in the relative abundance of the smallest and largest components.
The arithmetic, laid out
One milligram of a compound contains 1/M millimoles, where M is its molecular weight in daltons. For these four that gives 2.92 micromoles per milligram for KPV, 2.48 for GHK-Cu, 1.12 for TB-500 and 0.704 for BPC-157. So a milligram of KPV contains 4.15 times as many molecules as a milligram of BPC-157. If the 80mg were split evenly - 20mg of each - the molar ratio would be 4.15 : 3.52 : 1.60 : 1.00 running from KPV down to BPC-157, and the vial would contain four times more KPV molecules than BPC-157 molecules despite containing exactly the same mass of both.
Research material referenced
KLOW 80mg — third-party HPLC tested
What an equimolar blend would have to look like
Run the calculation the other way. For equal numbers of molecules, the masses must be in proportion to the molecular weights. Across an 80mg total that gives approximately 8.97mg of KPV, 10.56mg of GHK-Cu, 23.29mg of TB-500 and 37.19mg of BPC-157. An equimolar KLOW is therefore 37mg of BPC-157 and 9mg of KPV - a composition that looks nothing like an even split and would appear, to anyone reading masses, to be heavily weighted toward one component when in molecular terms it is perfectly balanced.
Neither reading is more correct than the other
There is no convention that settles this. Equal mass is the simpler thing to manufacture and the more natural reading of an unqualified total. Equal molarity is the more defensible thing pharmacologically, because it puts the components on comparable footing at their targets. A ratio chosen for some other reason - matching the proportions used in the separate literatures, say - is a third possibility and would be as legitimate as either. The problem is not that one is right; it is that the label does not say, and the difference between the readings is large enough to matter to any calculation performed downstream.
Why this compounds every other limitation
The split being unstated is already the known limitation of this format. The molar arithmetic makes the size of that gap concrete rather than abstract. Anyone reconstituting a vial and calculating a concentration is producing a number for the blend as a whole; converting it to a per-component molar concentration requires the split, and the plausible splits are separated by a factor of four at the extremes. That is not a rounding error. It is the difference between two experiments.
What would fix it
A stated per-component mass on the certificate. Not a ratio expressed as a proportion of the total, which is better than nothing but still requires the reader to do this conversion; the actual milligrams of each of the four. That single line would make per-component molar calculation possible and would cost the supplier nothing they do not already know, since the components are weighed separately before combining. Until it appears, any molar figure attached to a blend is an assumption wearing a number's clothes. KLOW and its components are supplied for laboratory research only and none of them holds a marketing authorisation.
Quick reference
| Component | MW (Da) | micromol per mg | If split evenly (20mg each) | If equimolar (80mg total) |
|---|---|---|---|---|
| KPV | 342.43 | 2.92 | 4.15 relative molecules | 8.97 mg |
| GHK-Cu | 402.92 | 2.48 | 3.52 relative molecules | 10.56 mg |
| TB-500 | 889.0 | 1.12 | 1.60 relative molecules | 23.29 mg |
| BPC-157 | 1419.5 | 0.704 | 1.00 relative molecules | 37.19 mg |
Extended research context
The KLOW (Blend) deep dive
Deep dive: a fourfold size range in one cake, and what partial dissolution hides
KLOW's components run from KPV at 342.43 daltons to BPC-157 at 1419.5 - a fourfold span, and the widest of any product in this catalogue. Solubility depends on size, charge distribution and hydrophobicity, and these four differ in all three, so a co-lyophilised cake containing all of them releases its components in sequence rather than together. The hazard follows directly and is easy to miss: a cake that looks partly dissolved is not uniformly partly dissolved. The smallest component may be entirely in solution while the largest has barely started. Draw from the vial at that moment and the sample is enriched in the fast components and depleted in the slow ones - a composition error with no visible sign at all, since the liquid looks like liquid. The instinctive response to visible solid makes it worse: shaking creates air-liquid interfaces, which is exactly where peptides unfold and then aggregate irreversibly. The correct response is diluent down the vial wall, gentle swirling, and more patience than a single peptide or even a three-component blend requires. There is a second asymmetry on top. Small peptides adsorb to glass and plastic more readily than large ones, so KPV is the component most likely to be lost to container walls at low concentration - a silent shift in the effective ratio that no certificate figure accounts for.
Deep dive: the cleanest possible comparison, which still cannot be run
KLOW is a strict superset of GLOW - the same three components plus KPV, at 80 mg against 70 mg. Product comparisons rarely have this structure. There is nothing in GLOW that KLOW lacks, so the difference between them reduces to a single question rather than a balance of trade-offs, and in principle comparing the two would isolate exactly what KPV contributes. In practice it cannot be done. The 10 mg difference in total might be 10 mg of added KPV with the other three unchanged, or it might be a redistribution across all four; both are consistent with the published figures, and neither product states its split. So any difference observed between the two could be KPV, or it could be a changed concentration of GHK-Cu, BPC-157 or TB-500. The experiment that the product pairing seems designed to permit is precisely the one the missing information forbids. This is the fixed-ratio limitation in its sharpest form: not that the format is unhelpful in general, but that it withholds the one number that would make the most natural question answerable.
Deep dive: two products from one hormone, in categories that never mention each other
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, isolated because that hormone does two functionally separable things - pigmentation through melanocortin receptors, and anti-inflammatory activity localised to its C-terminal end. KPV keeps the second and discards the first. Now look elsewhere in this catalogue: MT-2 is also an alpha-MSH derivative, and it is built around the melanocortin-receptor-binding core that KPV was specifically designed to leave behind. Two products, one parent hormone, opposite halves of its function, sitting in entirely separate product categories with nothing in either listing to indicate they are related. The size difference tracks the design logic. KPV at 342.43 daltons is three residues with no modifications, because an effect running through diffuse intracellular signalling can survive extreme truncation. MT-2 at 1024.2 daltons is seven residues plus a lactam bridge, a D-amino acid and two capped termini, because receptor engagement requires enough structure to present a specific surface. What a fragment needs to be depends entirely on what the retained function requires, and these two are as clean an illustration of that as this catalogue contains.
Research applications
- ▸Multi-component connective tissue research protocols
- ▸Comparative work on three-component versus four-component combinations
- ▸Co-lyophilisation and multi-component dissolution methodology
- ▸Copper peptide compatibility studies
- ▸Surface adsorption behaviour across a wide molecular size range
- ▸Anti-inflammatory and matrix pathway research
Handling checklist
- ✓Verify KPV as Lys-Pro-Val at 342.43 Da, CID 125672 - never by searching 'KPV'
- ✓Verify GHK-Cu against 402.92 Da (CID 71587328), not 340.38 for free GHK
- ✓Verify TB-500 against 889.0 Da, not 4.9 kDa for thymosin beta-4
- ✓Verify BPC-157 against 1419.5 Da
- ✓Expect four separate certifications - a single combined purity figure is a category error
- ✓Allow more dissolution time than a three-component blend; do not draw before it completes
- ✓Use low-binding consumables - KPV is the component most lost to surfaces
- ✓Store lyophilised, cold, dry and dark; the copper complex governs light protection
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Drawing from a partly dissolved four-component cake
Fix: Components dissolve in sequence across a fourfold size range. An early sample is enriched in fast components and depleted in slow ones, with no visible sign.
✗ Verifying the KPV component by searching 'KPV' in PubChem
Fix: That returns 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.
✗ Assuming the 10mg difference from GLOW is 10mg of KPV
Fix: Not stated. It could be added KPV with the others unchanged, or a redistribution across all four.
✗ Treating four component literatures as evidence about the blend
Fix: No published work addresses this combination or any subset of it. Summing separate literatures produces no evidence about a mixture.
✗ Adding a chelator because the blend contains copper
Fix: Unnecessary. None of the four components contains cysteine or methionine, so copper-catalysed oxidation has no substrate here.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- What does adding KPV to a three-component blend actually change?
- Why can comparing KLOW with GLOW not isolate KPV's contribution?
- What does a fourfold size range mean for how a blend dissolves?
- Which component is most likely to be lost to container surfaces?
- How are KPV and MT-2 related through alpha-MSH?
- What can a four-component certificate never establish?
Frequently asked questions
- Is the split stated anywhere?
- No. The product is described by a total mass across four components. That is the format's standing limitation and it is why the two columns on the right of the table above cannot be resolved into one.
- Which split do suppliers usually use?
- There is no way to know without the certificate saying so, and assuming is exactly the error this article is about. A supplier that weighs the components separately - which is how a co-lyophilised blend is made - already has the figures.
- Does this matter if I only compare the blend with itself?
- Much less. A single fixed composition compared across conditions is internally consistent whatever the split is. It matters when converting to molar concentrations, when comparing with published work on an individual component, or when comparing two products.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemKPV (Lys-Pro-Val), PubChem CID 125672pubchem.ncbi.nlm.nih.gov
- PubChemGHK-Cu (prezatide copper), PubChem CID 71587328pubchem.ncbi.nlm.nih.gov
- PubChemTB-500 heptapeptide, PubChem CID 62707662pubchem.ncbi.nlm.nih.gov
- PubChemBPC-157, PubChem CID 9941957pubchem.ncbi.nlm.nih.gov
- PubMedKannengiesser K et al., Melanocortin-derived tripeptide KPV in murine colitis — Inflamm Bowel Dis 2008 (PMID 18092346)pubmed.ncbi.nlm.nih.gov
- PubMedPickart L & Margolina A, GHK Peptide as a Natural Modulator of Multiple Cellular Pathways — Biomed Res Int 2015 (PMID 26236730)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157 — Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · BPC 157 Phase 2 in hamstring strain (NCT07437547)clinicaltrials.gov
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More KLOW (Blend) articles
- Half of This Blend Is Small Enough to Share a RouteKPV is a demonstrated PepT1 substrate. GHK is also a tripeptide. Whether the two compete for the same carrier has never been asked, let alone answered.
- The Ratio in the Vial Is Not the Ratio Anything SeesA co-formulation fixes the ratio at the moment of dosing and at no moment after it. Components with different stability then diverge from those proportions.
- Sixteen Arms Before You Have Asked a Single QuestionTesting whether four components do anything together requires a factorial design. For four components that is sixteen separate groups at one dose level each.
- One Thing This Blend Makes Easy342, 403, 889 and 1420 daltons are widely and unevenly spaced. No two components are close enough to confuse, which makes the identity check straightforward.
- KLOW Has No CAS Number, and It Cannot Have OneBlend names are supplier designations, not chemical identifiers. There is no PubChem record, no CAS registry number and no standard composition behind one.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchRetatrutide in the Published Literature
- GHK-Cu (Copper Peptide)Loren Pickart and the GHK Research Programme
- TB-500 (Thymosin β4 fragment)What Does TB-500 Stand For?
- BPC-157 (Pentadecapeptide)Tendon and Ligament Models
- CJC-1295 & IpamorelinThe Teichman 2006 CJC-1295 Study
- Peptide ReferenceHow Peptides Are Made
- Bacteriostatic WaterThe Diluent Makes Freeze-Thaw Worse
- Research & Regulatory NewsRetatrutide TRIUMPH-2 and TRIUMPH-3: What They Added
- GLP-1 & Incretin ScienceSTEP UP: Testing Whether More Dose Means More Effect
- MOTS-c (Mitochondrial Peptide)MOTS-c and Exercise: What the Published Research Shows
- Semax (ACTH Fragment Peptide)Semax in the Published Literature
- Selank (Tuftsin Analogue)Selank Structure, Sequence and Physical Properties
- DSIP (Delta Sleep-Inducing Peptide)A Question Mark in the Title Is Doing Real Work
- GLOW (Blend)Storing a Blend: The Weakest Component Governs
- MT-2 (Melanotan II)The Pharmacology Works. This Compound Was Not Developed.
- IGF-1 LR3Two Hormones, One Feedback Loop
- GlutathioneAn Enzyme Family That Uses Glutathione as a Reagent
- NAD+DNA Damage Draws Down the Pool
- KPVA Second Claim, With a Different Mechanism